A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F24%3AE0111237" target="_blank" >RIV/00843989:_____/24:E0111237 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/24:A25039MI
Result on the web
<a href="https://www.tandfonline.com/doi/full/10.1080/14796694.2024.2394323" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/14796694.2024.2394323</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14796694.2024.2394323" target="_blank" >10.1080/14796694.2024.2394323</a>
Alternative languages
Result language
angličtina
Original language name
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
Original language description
This summary describes the first analysis of the PERSEUS study, which looked at adults with multiple myeloma that had never been treated before, also called newly diagnosed multiple myeloma. Multiple myeloma is a type of cancer in the blood, specifically in plasma cells within the soft, spongy tissue in the center of most bones, called the bone marrow. Researchers wanted to see if adding daratumumab (D) to a standard treatment of three other medicines called VRd, which stands for bortezomib (V), lenalidomide (R), and dexamethasone (d), could stop the multiple myeloma from getting worse and help participants live longer without multiple myeloma.Half of the participants were assigned to the treatment plan with daratumumab; they received D-VRd during initial treatment phases (induction and consolidation), followed by daratumumab as well as lenalidomide (D-R) in the maintenance phase. The other half of participants received treatment without daratumumab; they received VRd induction and consolidation followed by lenalidomide alone (R) maintenance. In addition, all participants were able to receive an autologous stem cell transplant, a procedure used to further help reduce multiple myeloma.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Future oncology
ISSN
1479-6694
e-ISSN
1744-8301
Volume of the periodical
20
Issue of the periodical within the volume
38
Country of publishing house
GB - UNITED KINGDOM
Number of pages
21
Pages from-to
3043-3063
UT code for WoS article
001315029700001
EID of the result in the Scopus database
2-s2.0-85204805039